Storey Robert F
Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield Sheffield, UK.
Interv Cardiol. 2024 May 14;19:e07. doi: 10.15420/icr.2023.44. eCollection 2024.
For patients presenting with acute or chronic coronary syndromes, current guideline recommendations and expert consensus provide a range of options for antithrombotic treatment. The European Society of Cardiology 2023 guidelines on the management of acute coronary syndrome emphasise the need to assess the risk of both ischaemic events and bleeding. Those with high bleeding risk warrant particular consideration of the duration and intensity of antithrombotic therapy combinations. A joint consensus of experts takes a similar approach, informed by two network meta-analyses that appraised all available antithrombotic treatments within or after the 12 months following coronary revascularisation and/or acute coronary syndrome and individual participant data from six trials. In this article, four case studies are used to illustrate how these guidelines and expert consensus recommendations can be applied in clinical practice.
对于患有急性或慢性冠状动脉综合征的患者，当前的指南建议和专家共识提供了一系列抗血栓治疗选择。欧洲心脏病学会2023年急性冠状动脉综合征管理指南强调需要评估缺血事件和出血的风险。出血风险高的患者需要特别考虑抗血栓治疗组合的持续时间和强度。专家联合共识采取了类似的方法，这是基于两项网络荟萃分析得出的，这两项分析评估了冠状动脉血运重建和/或急性冠状动脉综合征后12个月内或之后的所有可用抗血栓治疗方法，以及来自六项试验的个体参与者数据。在本文中，使用了四个案例研究来说明这些指南和专家共识建议如何应用于临床实践。
